Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Concord Medical Services Holdings Limited
Concord Medical runs radiotherapy and diagnostic imaging centers and sells medical equipment and medicines to hospitals in China.
Concord Medical is a healthcare services company in China that helps hospitals treat cancer patients. It builds and operates radiation therapy and diagnostic imaging centers inside hospitals, mostly in smaller cities where advanced cancer care is scarce. The company installs the equipment — machines that blast tumors with radiation and scanners that find them — then runs the centers and splits the money with the hospital. Patients get treated close to home instead of traveling to a big-city hospital.
The company makes money in three main ways. It earns a share of the fees when patients use its centers. It leases medical equipment to hospitals that want the machines but not a full partnership. And it sells medicines and supplies to hospitals, mostly cancer drugs. Hospitals choose Concord because buying a linear accelerator costs millions and requires expertise they often lack; Concord brings the machines, the technicians, and the know-how, and takes a cut of each treatment. The business has had a rough ride. Concord went public on the NYSE in 2009, but its American depositary shares were delisted from the NYSE in 2022, though they continue trading on the OTC market. China's crackdown on drug pricing and hospital procurement, plus the country's slow economic recovery, have squeezed revenue and margins. The company has reported losses in recent years, and its share price has collapsed far below its 2009 IPO level — a reminder that a good-sounding mission does not guarantee a good investment.
Concord's real asset is its network of centers and its relationships with hundreds of Chinese hospitals, many in places where decent cancer care is genuinely hard to find. But it is a small player in a giant market, competing with larger equipment makers and hospital groups, and it depends on government policy and hospital budgets it cannot control. For a curious investor, the takeaway is simple: Concord sells access to cancer treatment infrastructure in China's hinterland, and its fortunes rise and fall with Chinese healthcare spending.
Saved answer · last researched 15 Nov 2026